NCT01923610View on ClinicalTrials.gov

Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

HIV Infections

Interventions

BIOLOGICAL

Experimental

"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-\~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"

Trial Locations (2)

28007

Hospital Universitario Gregorio Marañón, Madrid

08036

Hospital Clínic i Provincial de Barcelona, Barcelona

All Listed Sponsors

lead

Hospital Clinic of Barcelona

OTHER

NCT01923610 - Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B | Biotech Hunter | Biotech Hunter